DURECT Corporation (DRRX) EPS Estimated At $-0.06

July 14, 2018 - By Marguerite Chambers

DURECT Corporation (NASDAQ:DRRX) LogoInvestors sentiment decreased to 1.71 in 2018 Q1. Its down 0.33, from 2.04 in 2017Q4. It fall, as 6 investors sold DURECT Corporation shares while 22 reduced holdings. 20 funds opened positions while 28 raised stakes. 70.89 million shares or 9.45% more from 64.77 million shares in 2017Q4 were reported.
1.76M were reported by Renaissance Tech Ltd Liability Com. Alliancebernstein L P reported 21,500 shares. California State Teachers Retirement Systems owns 221,728 shares or 0% of their US portfolio. Ameriprise Financial invested in 0% or 196,702 shares. Davenport & Co Ltd Liability Co invested in 0% or 342,000 shares. Cetera Ltd Llc reported 11,467 shares stake. Geode Cap Mgmt Limited has 1.38 million shares for 0% of their portfolio. Cubist Systematic Strategies Ltd Com has invested 0.01% in DURECT Corporation (NASDAQ:DRRX). Gagnon Securities Limited Liability Com owns 1.13M shares. Plante Moran Financial Advsr Limited Liability Co invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Stoneridge Invest Prns Ltd Liability Com holds 0.01% in DURECT Corporation (NASDAQ:DRRX) or 14,463 shares. Schwab Charles Inv Management holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 263,476 shares. Jpmorgan Chase stated it has 28,883 shares or 0% of all its holdings. Prudential Incorporated holds 0% or 13,940 shares in its portfolio. Kings Point has 655,000 shares.

Analysts expect DURECT Corporation (NASDAQ:DRRX) to report $-0.06 EPS on August, 14.They anticipate $0.01 EPS change or 14.29 % from last quarter’s $-0.07 EPS. After having $-0.05 EPS previously, DURECT Corporation’s analysts see 20.00 % EPS growth. The stock increased 1.83% or $0.03 during the last trading session, reaching $1.67. About 283,458 shares traded. DURECT Corporation (NASDAQ:DRRX) has risen 56.35% since July 14, 2017 and is uptrending. It has outperformed by 43.78% the S&P500.

DURECT Corporation (NASDAQ:DRRX) Ratings Coverage

Among 2 analysts covering Durect Corp (NASDAQ:DRRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Durect Corp had 2 analyst reports since March 2, 2018 according to SRatingsIntel. Stifel Nicolaus maintained the shares of DRRX in report on Friday, March 2 with “Hold” rating. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 6.

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company has market cap of $270.05 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. It currently has negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.

More news for DURECT Corporation (NASDAQ:DRRX) were recently published by: Streetinsider.com, which released: “After-Hours Stock Movers 06/26: (DAC) (WWE) Higher; (DRRX) (SONC) (SBLK) Lower (more…)” on June 26, 2018. Streetinsider.com‘s article titled: “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” and published on June 27, 2018 is yet another important article.

DURECT Corporation (NASDAQ:DRRX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.